Trial Profile
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Relmacabtagene-autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Diffuse large B cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 06 Nov 2019 Results of trials NCT03344367 and NCT03355859 released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 Results of a pooled data analysis from NCT03344367 and NCT03355859 trials released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 23 Aug 2019 Results published in the Clinical Cancer Research